Key terms
About SKYE
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include Nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SKYE news
Apr 30
5:55am ET
Skye Bioscience management to meet with Oppenheimer
Apr 29
4:55am ET
Skye Bioscience management to meet with Oppenheimer
Apr 26
8:30am ET
Skye Bioscience management to meet with Oppenheimer
Apr 17
4:55am ET
Skye Bioscience management to meet with Morgan Stanley
Apr 14
1:42pm ET
Skye Bioscience management to meet with Morgan Stanley
Apr 12
5:05am ET
Skye Bioscience initiated with an Outperform at Oppenheimer
No recent press releases are available for SKYE
SKYE Financials
Key terms
Ad Feedback
SKYE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SKYE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
